HK1250944A1 - 用於治疗癌症的方法 - Google Patents

用於治疗癌症的方法 Download PDF

Info

Publication number
HK1250944A1
HK1250944A1 HK18110438.9A HK18110438A HK1250944A1 HK 1250944 A1 HK1250944 A1 HK 1250944A1 HK 18110438 A HK18110438 A HK 18110438A HK 1250944 A1 HK1250944 A1 HK 1250944A1
Authority
HK
Hong Kong
Prior art keywords
methods
treating cancer
compound
kits
administering
Prior art date
Application number
HK18110438.9A
Other languages
English (en)
Chinese (zh)
Inventor
Chiang J. Li
Wei Li
Youzhi Li
Matthew J. HITRON
Yuan Gao
Original Assignee
Boston Biomedical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical, Inc. filed Critical Boston Biomedical, Inc.
Publication of HK1250944A1 publication Critical patent/HK1250944A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18110438.9A 2015-04-17 2016-04-18 用於治疗癌症的方法 HK1250944A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562149349P 2015-04-17 2015-04-17
US201562149349P 2015-04-17
US201662280947P 2016-01-20 2016-01-20
US201662280947P 2016-01-20
PCT/US2016/028177 WO2016168856A1 (en) 2015-04-17 2016-04-18 Methods for treating cancer

Publications (1)

Publication Number Publication Date
HK1250944A1 true HK1250944A1 (zh) 2019-01-18

Family

ID=55854799

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110438.9A HK1250944A1 (zh) 2015-04-17 2016-04-18 用於治疗癌症的方法

Country Status (16)

Country Link
US (1) US20180085341A1 (cg-RX-API-DMAC7.html)
EP (1) EP3283069A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018511643A (cg-RX-API-DMAC7.html)
KR (1) KR20180006918A (cg-RX-API-DMAC7.html)
CN (1) CN107666906A (cg-RX-API-DMAC7.html)
AU (1) AU2016247319A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017022281A2 (cg-RX-API-DMAC7.html)
CA (1) CA2983010A1 (cg-RX-API-DMAC7.html)
EA (1) EA201792287A1 (cg-RX-API-DMAC7.html)
HK (1) HK1250944A1 (cg-RX-API-DMAC7.html)
IL (1) IL255022A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017013360A (cg-RX-API-DMAC7.html)
PH (1) PH12017501879A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201900564WA (cg-RX-API-DMAC7.html)
TW (1) TW201713327A (cg-RX-API-DMAC7.html)
WO (1) WO2016168856A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
US20190076392A1 (en) * 2016-01-20 2019-03-14 Boston Biomedical, Inc. Methods for treating cancer
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
JP7399079B2 (ja) * 2017-09-05 2023-12-15 エピザイム，インコーポレイティド 癌を処置するための併用療法
CA3115869A1 (en) * 2018-10-12 2020-04-16 1Globe Biomedical Co., Ltd. New combination solution for treating chemotherapy refractory cancer
EP3705893A1 (en) * 2019-03-05 2020-09-09 Humanitas Mirasole S.p.A. Methods to assess the risk of being affected by prostate cancer
CN113906298B (zh) * 2019-03-27 2024-12-20 新加坡保健服务集团有限公司 对腹膜癌扩散具有治疗意义的生物标志物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190429B1 (en) * 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
ES2659541T3 (es) 2010-03-19 2018-03-16 1Globe Biomedical Co., Ltd. Compuestos y composiciones novedosas para direccionar hacia células madre del cáncer
BR112012023660B8 (pt) 2010-03-19 2021-05-25 Boston Biomedical Inc usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
WO2012119265A1 (en) 2011-03-04 2012-09-13 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
JP6433085B2 (ja) * 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
US20190076392A1 (en) * 2016-01-20 2019-03-14 Boston Biomedical, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
BR112017022281A2 (pt) 2018-07-10
JP2018511643A (ja) 2018-04-26
CA2983010A1 (en) 2016-10-20
TW201713327A (zh) 2017-04-16
MX2017013360A (es) 2018-08-01
US20180085341A1 (en) 2018-03-29
CN107666906A (zh) 2018-02-06
IL255022A0 (en) 2017-12-31
PH12017501879A1 (en) 2018-03-05
SG10201900564WA (en) 2019-02-27
AU2016247319A1 (en) 2017-11-02
KR20180006918A (ko) 2018-01-19
WO2016168856A1 (en) 2016-10-20
EP3283069A1 (en) 2018-02-21
SG11201708504XA (en) 2017-11-29
EA201792287A1 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
AU2022231657A1 (en) Compositions and Methods for Treating Cancer
HK1258098A1 (zh) 治疗癌症的方法
HK1250944A1 (zh) 用於治疗癌症的方法
EP3258966A4 (en) Methods, compositions, and kits for treatment of cancer
EP3548071A4 (en) METHOD FOR TREATING CANCER WITH TIGIT-BINDING ACTIVE SUBSTANCES
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
EP3393475A4 (en) METHODS OF TREATING CANCER
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
IL261015A (en) History of methylamine as lysis oxidase inhibitors for cancer treatment
IL268163A (en) Methods, compositions, and kits for treatment of cancer
EP4616910A3 (en) Pcna inhibitors
MX2016009663A (es) Derivados de icariina.
EP3394047A4 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
PH12017501880A1 (en) Methods for treating cancer
EP3487999A4 (en) METHODS OF TREATING CANCER
EP4169918B8 (en) Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer
EP3296294A4 (en) Compound for treating or preventing breast cancer
EP3303289A4 (en) Compounds and methods for treating cancer
EP3592357A4 (en) METHOD OF TREATMENT OF CANCER
EP3242681B8 (en) Novel compounds for the treatment of cancer
EP3268028A4 (en) Compositions and methods for treating cancer
EP3285763A4 (en) Compositions for the treatment of cancer
HK40093247A (zh) 治疗癌症的组合物及方法
HK40091839A (zh) 用於治疗癌症的方法和组合物